Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TSHA
#1815
Taysha Gene Therapies, Inc. Common Stock
4.5
3
+0.44%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+0.44%
Changement Mensuel
-4.43%
Evolution sur 6 mois
+51.51%
Changement Annuel
+177.91%
Clôture Précédente
4.5
1
Open
4.5
3
Bid
Ask
Low
4.5
3
High
4.5
3
Volume
115
Marchés
Actions des Marchés US
Soins de Santé
TSHA
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
204.94 M
205 M
214.66 M
272.79 M
273.92 M
—
Valuation ratios
Enterprise value
254.25 M
215.62 M
181.79 M
317.4 M
598.37 M
1.31 B
Price to earnings ratio
5.91
-4.81
-4.09
-6.79
-9.91
-25.6
Price to sales ratio
35.12
51.93
49.49
77.07
140.37
318.86
Price to cash flow ratio
5.06
5.33
4.24
7.61
11.23
28.41
Price to book ratio
1.2
6.05
1.08
1.39
1.68
10.2
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.14
0.12
0.16
0.08
0.1
0.46
Return on equity %
0.29
0.26
0.39
0.11
0.15
0.91
Return on invested capital %
257.93
221.99
263.06
359.78
441.35
1 286.18
Gross margin %
100
100
100
100
—
—
Operating margin %
1 448.43
985.76
930.54
1 347.08
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 427.52
929.03
935.23
1 353.58
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.51
5.42
5.35
12.48
10.48
33.72
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.01
0.02
0.01
0
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.24
0.27
0.31
0.12
0.16
0.86
Long term debt to total equity ratio
0.48
0.61
0.77
0.17
0.23
1.78
Per share metrics
Operating cash flow per share
0.08
0.07
0.08
0.07
0.07
0.29
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
0.59
0.56
0.43
1.05
0.84
2.88
Net current asset value per share
0.6
0.57
0.45
1.06
0.85
2.93
Tangible book value per share
0.33
0.29
0.2
0.83
0.62
1.94
Working capital per share
0.49
0.46
0.36
0.98
0.77
2.57
Book value per share
0.33
0.29
0.2
0.83
0.62
1.94
Nouvelles
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
Taysha Gene Therapies stock hits 52-week high at $5.98
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock
Taysha Gene Therapies stock hits 52-week high at 5.51 USD
Goldman Sachs upgrades Taysha Gene Therapies stock rating to Buy
Nagendran Sukumar sells Taysha gene therapies (TSHA) shares for $1.69m
Cantor Fitzgerald maintains Overweight rating on Taysha Gene Therapies stock
Neurogene stock price target raised to $70 from $65 at H.C. Wainwright
Taysha Gene Therapies stock price target raised to $8 at Citizens
Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript